Imunon Inc. is a fully integrated, clinical stage biotechnology company. It focused on advancing a portfolio of treatments which harness the body's natural mechanisms. The company's lead clinical program includes GEN-1. Imunon Inc., formerly known as Celsion Corporation, is based in LAWRENCEVILLE, N.J.
| Revenue (Most Recent Fiscal Year) | $0.50M |
| Net Income (Most Recent Fiscal Year) | $-18.62M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 64.37 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -427.98% |
| Return on Assets (Trailing 12 Months) | -175.03% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.88 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.88 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.03 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.28 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.62 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.36 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 17.54M |
| Free Float | 16.66M |
| Market Capitalization | $34.91M |
| Average Volume (Last 20 Days) | 29.46M |
| Beta (Past 60 Months) | 1.75 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 4.47% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |